Efficacy and Safety of 2 Vedolizumab Intravenous Regimens for Perianal Fistulizing Crohn ’s Disease: ENTERPRISE Study

We report results from ENTERPRISE, a randomized, double-blind, phase 4 trial, evaluating 2 vedolizumab intravenous dosing regimens in patients with fistulizing CD.

Source: Clinical Gastroenterology and Hepatology - September 28, 2021 Category: Gastroenterology Authors: David A. Schwartz, Laurent Peyrin-Biroulet, Karen Lasch, Shashi Adsul, Silvio Danese Source Type: research